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Dengue fever is a mosquito-borne viral disease that has become a major public health 
concern worldwide. This disease presents with a wide range of clinical manifestations, 
from a mild cold-like illness to the more serious hemorrhagic dengue fever and dengue 
shock syndrome. Currently, neither an approved drug nor an effective vaccine for the 
treatment are available to fight the disease.  
The envelope protein (E) is a major component of the virion surface. This protein 
plays a key role during the viral entry process, constituting an attractive target for the 
development of antiviral drugs. The crystal structure of the E protein reveals the 
existence of a hydrophobic pocket occupied by the detergent n-octyl-β-d-glucoside 
(β-OG). This pocket lies at the hinge region between domains I and II and is 
important for the low pH-triggered conformational rea rangement required for the 
fusion of the virion with the host’s cell. Aiming at the design of novel molecules 
which bind to E and act as virus entry inhibitors, we undertook a de novo design 
approach by “growing” molecules inside the hydrophobic site (β-OG). From more 
than 240000 small-molecules generated, the 2,4 pyrimidine scaffold was selected as 
the best candidate, from which one synthesized compound displayed micromolar 
activity. Molecular dynamics-based optimization was performed on this hit, and thirty 
derivatives were designed in silico, synthesized and evaluated on their capacity to 
inhibit dengue virus entry into the host cell. Four compounds were found to be potent 
antiviral compounds in the low-micromolar range. The assessment of drug-like 
physicochemical and in vitro pharmacokinetic properties revealed that compounds 3e 
and 3h presented acceptable solubility values and were stable in mouse plasma, 
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Dengue fever is the most prevalent mosquito-borne viral disease and has become a 
major public health concern worldwide in recent years. Dengue virus (DENV) belongs 
to the genus Flavivirus (Flaviviridae), which are positive-sense single-stranded RNA 
genome viruses, as several other human pathogens such as West Nile, Japanese 
encephalitis and Zika viruses [1–3]. To date, four se otypes of DENV have been 
described, i.e., DENV1 to DENV4. At present, DENV is endemic in more than 100 
countries worldwide [4]. The Americas, South-East Aia and Western Pacific are the 
most seriously affected regions. During 2016 serious tbreaks occurred worldwide, 
with more than 2.3 million cases being reported in the Americas [5,6].  
Controlling DENV epidemic outbreaks remains difficult. Dengue vaccine (Dengvaxia) 
developed by Sanofi Pasteur has been listed in morethan 10 countries to prevent dengue 
fever [7–9]. However, vaccination requires a three-dose regimen that is limited to 
individuals aged 9–45 years old, and in seronegative individuals provides modest 
protection[10]. Currently, there is still no specific antiviral to fight the disease Although 
some drugs have been proposed for different DENV proteins, such as the viral 
polymerase and protease, none of them have been approved [10,11].  
The entry of viruses into the host cell is an early nd specific stage of infection of which 
different viral or cellular targets are sensitive to therapeutic intervention. The entry of 
DENV is initiated by the binding of the viral particle to receptors on the host cell’s 
plasma membrane, followed by internalization via receptor-mediated endocytosis of the 
virion into the cytosol. The acidic conditions of the endosome compartment trigger a 
conformational rearrangement of the viral envelope proteins (E) which induces the 
fusion of the viral and endosomal membranes creating a pore through which the viral 
genome is released into the host cell’s cytoplasm [12,13]. The crystal structure of 
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DENV-2 E protein reveals a hydrophobic pocket occupied by the detergent n-octyl-β-D-
glucoside (β-OG). This pocket lies at the hinge region between domains I and II of the E 
protein. The β-OG pocket is the region where the major conformational changes occur 
during membrane fusion. Several authors have proposed that small molecules 
interacting with the E protein can block viral entry. [13–15] The best pharmacological 
evidence for the pocket as a suitable target was published by Wispelaere t al. The 
authors demonstrated that pyrimidines analogs can bind extracellularly to the E protein, 
and prevent the infection by blocking E-mediated membrane fusion during viral entry. 
A resistance mutation, M196V, located adjacent to the β-OG pocket, reduces the 
affinity and viral infectivity of the evaluated compound [14]. The aim of this work was 
to identify new molecules that would bind to the β-OG pocket and inhibit DENV entry. 
To this end, a de novo design strategy was employed and the selected compound 
showed viral inhibition at micromolar concentrations. Through a lead optimization 
process, several optimized derivatives were obtained which displayed high 
improvement in the antiviral activity and pharmacokinetics in vitro properties 
(solubility, logP, and stability). 
2. Results and discussion 
2.1. Chemistry  
On the basis of the de novo design considerations (section 2.3), we prepared a range of 
2,4-disubstituted pyrimidine analogs (Scheme 1). The synthesis of pyrimidine analogs 
was based on previously described procedures [16]. The desired compounds were 
obtained through a SNAr reaction of anilines and amines with heteroaryl chlorides [17]. 
Compounds 2a-f and 4a-d were obtained in high yield by selective substitution in 
position 4 with commercially available or synthesizd anilines and benzylamines in the 
presence of DIPEA in n-butanol (2a-f) or ethanol (4a-d). Finally, the desired 
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compounds (3a-v and 5a-e) were prepared through a SNAr from monosubstituted 
pyrimidine, (2a-f and 4a-d) and the corresponding alkyl amines. Due to the lack of 
reactivity of the 2-position of N-4-pyrimidine derivatives, the reaction was carried out in 
sealed tube at reflux with a low yield.  
Compound 8, 11 and 12 were obtained as shown in scheme 2. The intermediate 
hydrazone (7) was obtained by the condensation of 4-hydrazino-2-chloro pyrimidine (6) 
with 2,4-dichlorobenzaldehyde. Compound 10 was prepared by the condensation of 5-
(pyridin-2-yl)thiophene-2-carboxylic acid and 2-chloropyrimidin-4-amine, in the 
presence of EDCI.HCl and HOBt in NMP. Compound 12 was prepared via a SNAr 




Scheme 1. General procedure for synthesis of compounds 3a-v and 5a-e. Reagents and conditions (a) Amines, DIPEA, n-butanol, 110°C, 





Scheme 2. Synthesis of compounds 8, 11 and 12. Reagents and conditions (a) NH2NH2, 
TEA, methanol, rt, 2 h. (b) 2,4-Dichlorobenzaldehyde, ethanol, reflux, 1 h. (c) 4-(2-
Aminoethyl)morpholine, DIPEA, 190°C, sealed vial. (d) NH4OH, 90°C, 5 h. (e) 5-
(Pyridin-2-yl)thiophene-2-carboxylic acid, EDCI·HCl, HOBt, NMP, rt, overnight, (f) 4-
(2-Hydroxyethyl)morpholine, NaH, THF, 80°C, overnight. 
2.2. Antiviral activity 
The antiviral activity was evaluated for each newly designed compounds monitoring the 
expression of the luciferase from a recombinant fully functional reporter infectious 
DENV-2 bearing a luciferase coding sequence. [18,19] After infection of cells in culture 
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with the reporter DENV, the luciferase activity peaks at 8 h as a result of the translation 
of the incoming viral genome. Thus, luciferase activity at this time point reflects entry 
of the reporter virus. After 24 h post-infection, the genome amplification by the viral 
polymerase occurs, leading to an increase in the luciferase activity, which accounts for 
the synthesis of viral RNA. The luciferase activity was measured at 8 h post-infection 
with the reporter DENV in either untreated control and in cells treated with each of the 
thirty compounds synthesized (Tables 1 and 2). Two of the active inhibitors, that block 
an early infection step,  were further evaluated for their antiviral activity against fully 
DENV1-4 infectious viral particles by a virus yield inhibition assay [20]. Cells were 
infected at a multiplicity of infection (m.o.i.) of 0.1 plaque formation units per cell 
(PFU/cell) and further incubated in the presence of different compound concentrations 
during 24 and 48 h. Virus replication was inhibited by both compounds in a dose-
dependent manner attaining a reduction higher than 50% in virus titres in the range of 
concentrations 0.3-1.5 µM for all DENV serotypes (Table 3).  
In parallel to antiviral activity, cell viability was measured after the treatment with 
different concentrations of each compound using cristal violet and the 3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, as described 
previously[21]. 
2.3. De novo design of DENV E protein inhibitors 
Taking into account the crystal structure of the binding site occupied by β-OG reported 
by Modis et al. [22], we designed new small organic molecules with the capacity to 
bind the E protein like the β-OG ligand. The β-OG pocket entrance contains some 
hydrophilic amino acid residues that could establish electrostatically favorable 
interactions with ligands (for example, Thr48, Glu49, Gln200, Gln271, and Thr280). 
Besides, several polar atoms present at the pocket entrance are suitable partners for 
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energetically favorable hydrogen bond interactions. The hydrophobic pocket, which is 
occupied by the n-octyl chain of the β-OG ligand in the crystal structure, is large 
enough to accommodate the hydrophobic groups present in small molecule inhibitors 
[14,23–27].  
Based on the chemical features and critical interacions with the β -OG binding site of 
the active compounds previously reported [27,28], we generated a virtual chemical 
library using the BOMB program [29]. The library was grown starting with NH3 as the 
core, which was positioned to form a hydrogen bond with the Thr48 carbonyl group. All 
templates were designed to fulfill these key requirements: (i) to deliver a hydrophobic 
group into the hydrophobic pocket, as the β-OG octyl chain; (ii) to incorporate an NH to 
the hydrogen bond with Thr48, and (iii) to incorporate polar substituents into the 
channel entrance. An extensive conformational search was performed for each ligand; 
each conformer was optimally positioned and the one with lowest energy was scored as 
output. The structure optimization was performed with the OPLS-AA force field[30]. 
The prime parameters for the analysis were the protein-ligand potential energy (EPL), 
the desolvation energy and surface-area burial for the ligand, and the drug-like predicted 
properties including solubility and cell permeability [31]. Around 240,000 molecules 
were then built to form the Phx‐NH‐Het‐U motif, where NH is a core, U is a 
solubilizing group, Het is a heterocyclic ring, and Phx is a substituted (X) phenyl ring 
(Ph). The top-25 scoring analogs are dominated by quinazoline and pyrimidine as Het. 
The top 5-analogs have chlorine at 4- and 5- phenyl position (PhX) and 2-
morpholinoethanamine, and piperazine as solubilizing group (U). In the end, we 
selected compound 3a based on the high EPL value, adequate drug-like predicted 
properties and synthetic feasibility compared to the rest of the candidates.  
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Next, we docked 3a within the binding site and performed a 100 ns molecu ar dynamics 
(MD) simulation to determine the stability of the predicted conformations by BOMB 
and to explore the putative binding mode of the select d ligands with the E protein. 
During the first 40 ns of the simulation, 3a established a hydrogen bond interaction 
between the N-H at position 4 of the pyrimidine structure and the OH of the Thr280 
(Figure 1A). The interatomic distance and the typical hydrogen bond angle were nearly 
2 Å and 160°, respectively (Figure S1). After establishing this interaction, the ligand 
moved slightly from the initial conformation to another conformation that remained 
stable for the rest of the simulation. No hydrogen bond interactions were detected 
during that period.  
Compound 3a was synthesized and cytotoxicity was evaluated in A549 cell line. Also, 
antiviral activity was tested by the luciferase-reporter DENV assay mentioned above 
[18,19]. This ligand displayed antiviral activity ag inst DENV-2 (EC50 23.6 µM) and no 
cytotoxicity was observed at 50 µM. Although the antiviral activity was moderate, it 
was considered a good starting point for lead optimization.  
2.4. Lead optimization 
Initial analogs of 3a. A computer-aided drug optimization was carried out in order to 
improve the antiviral activity of 3a. For this purpose, we used a combination of design 
using the BOMB software followed by docking/MD simulations. In the first step, the 
determination of the optimal substitution pattern (X) of the Ph scaffold was performed 
by BOMB. The best EPL scores were obtained by the introduction of voluminous 
substituents such as X= Ph group. Analogues were the docked within the binding site, 
followed by 100 ns MD simulations. We were thus able to confirm that the close 
contacts made by all the ligands and the E protein became stronger and more stable as 
the size of the X chain increased. Furthermore, the more voluminous ligands also 
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established stronger and more stable H bond interactions. In particular, the MD 
simulations of compound 3c and 3d revealed that the biphenyl ring group fitted very 
well in the hydrophobic pocket establishing an energetically favorable hydrophobic 
contact with Thr48, Val130, Leu135, Met196, Ile270, and Phe279 side chains. In 
particular, a strong hydrophobic interaction was oberved between the terminal aromatic 
ring of the biphenyl group and Phe193 at a distance of 5 Å. These ligands established 
stable hydrogen bond interactions with the E protein. Both of them presented a 
moderate hydrogen bond between the N-H at position 4 of the pyrimidine with the 
carbonyl O of the Thr48, (interatomic distances of 2.2 Å and a bond angle of 150o) 
(Figures S2 and S3). At the end of the simulation performed with 3d, this ligand was 
found to move slightly from the initial conformation to another conformation that 
remained stable for the rest of the measurement period, and a new hydrogen bond was 
formed between the O of the Ala50 and the N-H at position 2 of the pyrimidine. The 
interatomic distances and H bond angle were 1.9 Å and 160°, respectively (Figure S4).  
During the second half of the simulation, another H bond was formed between the N3 of 
3c and 3d and the backbone amide H of Ala50 (interatomic distance of 2.2 Å and a 
bond angle of 160°) (Figures S5 and S6). For the entire simulation period, the 
morpholine group remained exposed to the solvent (Figure 1B). The MD simulations 
revealed a common pattern of interaction with the β-OG pocket in the E protein, which 




Figure 1. Predicted interaction of active compounds 3a (A) and 3c (B) within the E 
protein binding site (PDB ID 1OKE) obtained by the molecular dynamics simulations. 
Based on the outcome of the MD simulations, compounds 3c and 3d were synthesized 
and evaluated in the early infection steps dengue antivirals using an assay that allows 
discriminating entry/translation and genome amplification. As expected, both 
compounds were 3- and 13-fold more active than the predecessor 3a, respectively. The 
influence of other substituents, at position 4 of the pyrimidine ring on the biological 
activity was also investigated. Compounds 8 and 11, whose aromatic rings were found 
to fit well in the hydrophobic pocket were more active than the reference compound 3a.
(Table 1, Figure S7). In addition, a pairwise comparison of the activities of compounds 
3c and 12 (EC50 = 8.6 vs. 39.7 µM) revealed the crucial role of the NH at positi n 2 of 




Table 1. Anti-DENV activity and cytotoxicity of compounds 3a-d, 8, 11 and 12. 
Core structure Compound R1 
EC50 








23.6±1.2 89.6±2.3 4 
3b 
 
21.3±1.6 >50 >2 
3c 
 
8.6±1.1 59.0±1.8 7 
3d 
 
1.8±1.0 10.2±0.9 5 
8 
 
10.6±1.0 76.5±1.8 8 
11 
 




39.7±1.1 NDc ND 
aEffective concentration 50%: concentration required to achieve a two-fold reduction of 
luciferase activity compared to control. Results represent the mean from at least two 
independent experiments analyzed by GraphPad Prism software. 
bCytotoxic concentration 50 is defined as a concentration required to reduce the viability of 
A549 cells by 50%, as determined by MTT method. Results represent the mean from at least 
two independent experiments. 
cND: Not determined. 
dSI: selectivity index (SI = CC50/EC50). 
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The next step in the study was to evaluate the influe ce of the terminal heterocyclic ring 
on the antiviral activity. Therefore, we replaced the ethylmorpholine scaffold of 3a by 
ethylpiperidine (3e), tetramethylpiperidine (3h), methylpyridine (3m), methylpyridine 
N-oxide (3p), and 4-methyl and N-ethanolpiperazine (3q and 3v, respectively). In 
general, all the compounds were active within the low micromolar range. These results 
demonstrate that the activity is more dependent on the size of the X chain than on the 
heterocyclic ring exposed to the solvent. In particular, 3e and 3h exhibited higher 
activity against DENV, as compared to the rest of compounds of the series (3c, 3h, 3m, 
3p, 3q and 3v). (Table 2). 
Analogs of 3h. Several 3h derivatives (EC50=0.8 µM) were synthesized and evaluated 
against DENV. In general, all derivatives exhibited activity in a low micromolar range, 
including compound 3g, which bears a p-chlorophenyl group at position 4 of the 
pyrimidine ring (EC50=1.9 µM). Compounds 3i and 3j, bearing a chlorine atom in p- 
and m-position of the biphenyl group, were the most potent compounds of this series, 
with EC50 values of 0.1 µM and 0.5 µM, respectively. These results were also 
corroborated by measuring intracellular viral RNA level after treatment with the 
compounds for 48 h post infection (p.i.) by qRT-PCR.  
Taking into account the activity of 3g, the X chain appears to have less influence on the 
biological activity, as compared to the rest of theseries (Tables 1 and 2). Further MD 
simulations revealed the existence of a stable electrostatic interaction between the NH 
charged group of the tetramethylpiperidine scaffold and Glu49 (Figure 2). The 
contribution of this residue to the calculated binding free energy was notably higher 
than that of the other residues, which explains whythe influence of the X chain on the 




Table 2. Anti-DENV activity and cytotoxicity of compounds 3e-v and 5a-e. 
 









0.8±0.2 18.1±1.0 23 
3f 
 







































1.8±1.1 21.1±1.3 12 
5c 
 
1.98±1.1 12.8±0.2 7 
5d 
 






























7.4±1.0 40±1.2 5 
3n 
 
4.1±1.1 25.7±1.2 6 
3o 
 
3.4±1.1 18.5±1.9 5 
5a 
 








4.6±0.9 25.1±1.2 5 
3r 
 


















aEffective concentration 50%: concentration required to achieve a two-fold reduction of 
luciferase activity compared to control. Results represent the mean from at least two 
independent experiments analyzed by GraphPad Prism software. 
bCytotoxic concentration 50 is defined as a concentration required to reduce the viability of 
A549 cells by 50%, as determined by MTT method. Results represent the mean from at least 
two independent experiments. 
cND: Not determined. 
dSI: selectivity index (SI = CC50/EC50). 
 
 









24.0±1.1 ND ND 
3v 
 
19.9±1.3 ND ND 
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Figure 2. Predicted interaction of compound 3h within the E protein β-OG binding site, 
obtained by molecular dynamics simulation. The electrostatic interaction and hydrogen bond are 
shown as violet and green dashed lines respectively.  
Since all DENV serotypes co-circulate simultaneously in several tropical and 
subtropical areas, the antiviral activity against ifectious virus particles of serotypes 1-4 
was further evaluated. Based on the high conservation of the residues involved in the 
interaction between protein E and ligands, we expected active compounds to display 
antiviral activity against the four serotypes of DENV. Compounds 3e and 3h were 
selected for evaluation because they presented high potency and better calculated 
physicochemical properties (solubility, clogP). As expected, both compounds were 
found to be active against the four DENV serotypes, with slight differences between 




Table 3. Antiviral activity profile of 3e and 3h against DENV serotypes. 
Compound EC50 (µM)
a 
 DENV-1 DENV-2 DENV-3 DENV-4 
3e 0.87±0.1 0.85±0.2 0.56±0.2 2.5±1.1 
3h 0.58±0.1 0.81±0.2 0.39±0.8 0.87±0.3 
aEffective concentration 50% (EC50) was calculated as the concentration required to reduce 
virus yield by 50% in the compound‐treated cell cultures compared with untreated ones at 48 h 
p.i. All determinations were performed in triplicate. Values represent the mean ± standard 
deviation from triplicate independent tests. 
2.5 Physicochemical and in vitro pharmacokinetic properties of the selected compounds 
The physicochemical properties of the most promising compounds (3e and 3h) were 
evaluated in vitro in terms of solubility and stability. The solubility was tested at three 
different pH values (1.2, 6.8, and 7.4) employing the shake-flask method [32]. 
Solubility data are summarized in Table 3. All compounds presented acceptable 
solubility values, which were within the range normally observed for oral drugs, i.e.,  4-
4000 µg/mL (corresponding to S values ranging from 10-2  to 10-5 M for compounds 
with a molecular weight of 400) [33]. The clogP values for the listed compounds ranged 
from 3 to 5, which are also within the range for oral drugs (0-5) [34]. Stability studies 
were conducted in PBS (pH 7.4), simulated intestinal fluid (SIF, pH 6.8), simulated 
gastric fluid (SGF, pH 1.2), and mouse plasma and both compounds were proven to be 




Table 4. Physicochemical and pharmacokinetics in vitro properties for 3e and 3h. 
















3e 506±17 324±29 32±6 4.7 > 120 > 120 > 120 > 120 
3h 76±10 580±49 93±6 5.0 > 120 > 120 > 120 > 120 
aExperimental solubility at pH 1.2, 6.4 and 7.4. Values are expressed as the mean ± standard 
deviation of two independent experiments run in triplicate. 
bcLog P: Predicted by the Qikprop software. [35] 
c SGF, SIF, PBS and mouse plasma stability  
3. Conclusions 
On the basis of our hit identification and lead optimization strategy, thirty new 
molecules were synthesized. Four of the new derivatives displayed significant anti-
DENV activity (EC50 <1 µM) targeting the early steps of viral infection. Two of the 
most promising compounds (3e and 3h) proved to be active against the four DENV 
serotypes. Both compounds showed adequate solubility and high stability profiles in 
different media. Taking all this into account we consider that the pyrimidine analogs are 
a good starting point for the development of novel antivirals against DENV infection. 
4. Experimental section 
4.1.Chemistry 
Column chromatography was carried out employing Merck silica gel (Kieselgel 60, 63-
200 µm). Precoated silica gel plates F-254 were used for thin-layer analytical 
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chromatography. NMR spectra were recorded on Bruker Biospin 600 MHz AVIII600, 
Bruker advance II 500 MHz and Bruker 300 MHz spectrometers at room temperature. 
Chemical shifts (δ) are reported in ppm and coupling constants (J) in Hertz. The mass 
spectrometer utilized was a Xevo G2S QTOF (Waters Corporation, Manchester, UK) 
with an electrospray ionization (ESI) source. The mass spectrometer was operated in 
positive and negative ion modes with probe capillary voltages of 2.5 and 2.3 kV, 
respectively. The sampling cone voltage was 30 V. The source and desolvation gas 
temperatures were set to 120 and 350 °C, respectively. The nitrogen gas desolvation 
flow rate was 600 L h−1 and the cone desolvation flow rate was 10 L h−1. The mass 
spectrometer was calibrated across the range of m/z 50−1200 using a 0.5 mM sodium 
formate solution prepared in 2- propanol/water (90:10 v/v). Data were drift corrected 
during acquisition using a leucine encephalin reference spray (LockSpray) infused at 2 
µL min−1. Data were acquired in the range of m/z 50−1200, and the scan time was set 
to 1 s. Data acquisition and processing were carried out using MassLynx, version 4.1 
(Waters Corp., Milford, MA, USA). 
4.1.1. General procedure for synthesis of compounds 2a-f. To a pressure round-bottom 
flask containing the mixture of 2,4-dichloropyrimidine (1) (2.0 mmol) and the 
corresponding amine (2.0 mmol) in n-butanol (5 mL), DIPEA was added (10.0 mmol) 
slowly to the solution. The mixture was stirred at 110 oC overnight. The products were 
obtained as solids, which were filtrated from the reaction mixture and recrystallized 
from ethanol. 
4.1.1.1. 2-chloro-N-(4-chlorophenyl)pyrimidin-4-amine (2a). Yield: 0.224 g, 46%. 1H 
NMR (600 MHz, CDCl3) δ 8.16 (d, J = 5.9 Hz, 1H), 7.40 – 7.36 (m, 2H), 7.31 – 7.27 
(m, 2H), 6.93 (br s, 1H), 6.55 (d, J = 5.9 Hz, 1H).  
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4.1.1.2. 2-chloro-N-(p-tolyl)pyrimidin-4-amine (2b). Yield: 0.380 g, 87%. 1H NMR 
(300 MHz, CDCl3) δ 8.11 (d, J = 5.9 Hz, 1H), 7.25 – 7.16 (m, 4H), 6.95 (s, 1H), 6.54 
(d, J = 5.9 Hz, 1H), 2.29 (s, 3H).  
4.1.1.3 N-((1,1'-biphenyl)-4-yl)-2-chloropyrimidin-4-amine (2c). Yield: 0.350 g, 53%. 
1H NMR (600 MHz, DMSO-d6) δ 10.14 (s, 1H), 8.19 (d, J = 5.9 Hz, 1H), 7.73 – 7.64 
(m, 6H), 7.46 (t, J = 7.7 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 6.81 (d, J = 5.9 Hz, 1H).  
4.1.1.4. 2-chloro-N-(4'-chloro-[1,1'-biphenyl]-4-yl)pyrimidin-4-amine (2d). Yield: 0.082 
g, 40%). 1H NMR (600 MHz, CDCl3) δ 8.16 (d, J = 5.9 Hz, 1H), 7.62 – 7.57 (m, 2H), 
7.53 – 7.49 (m, 2H), 7.44 – 7.39 (m, 4H), 7.01 (s, 1H), 6.65 (d, J = 5.9 Hz, 1H). 
4.1.1.5. 2-chloro-N-(3'-chloro-[1,1'-biphenyl]-4-yl)pyrimidin-4-amine (2e). Yield: 0.206 
g, 86%. 1H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 5.9 Hz, 1H), 7.60 (d, J = 8.7 Hz, 
2H), 7.47 – 7.41 (m, 4H), 7.40 – 7.36 (m, 2H), 7.13 (s, 1H), 6.67 (d, J = 5.9 Hz, 1H). 
 
4.1.1.6. 2-chloro-N-(4'-methyl-[1,1'-biphenyl]-4-yl)pyrimidin-4-amine (2f). Yield: 0.069 
g, 21%. 1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 5.8 Hz, 1H), 7.64 – 7.59 (m, 2H), 
7.50 – 7.47 (m, 2H), 7.39 – 7.35 (m, 2H), 7.29 – 7.25 (m, 2H, signal overlapping with 
CDCl3), 7.00 (s, 1H), 6.65 (d, J = 5.9 Hz, 1H), 2.41 (s, 3H). 
4.1.2. General procedure for synthesis of compounds 3a-v. To a solution of alkyl amine 
(1.0 mmol) and DIPEA (1.6 mmol) in n-butanol (1 mL), the corresponding 
monosubtituted pyrimidine (0.4 mmol) was added. Themixture was stirred and heated 
at 190 oC in a sealed vial, and the reaction progress was monitored by TLC. The 
reaction solution was poured into water and extracted with dichloromethane. The 
organic layer was sequentially washed with brine, dried over anhydrous Na2SO4 and 
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concentrated in vacuo. The crude product was purified by column chromatography 
(SiO2, dichloromethane/methanol). 
4.1.2.1. N4-(4-chlorophenyl)-N2-(2-(morpholin-4-yl)ethyl)pyrimidine-2,4-diamine (3a). 
Yield: 0.028 g, 25%. 1H NMR (600 MHz, CDCl3) δ 7.94 (d, J = 5.7 Hz, 1H), 7.36 (d, J
= 8.7 Hz, 2H), 7.32 – 7.28 (m, 2H), 6.56 (br s, 1H), 5.98 (d, J = 5.7 Hz, 1H), 5.36 (br s, 
1H), 3.74 – 3.70 (m, 4H), 3.49 (q, J = 5.7 Hz, 2H), 2.59 (t, J = 6.1 Hz, 2H), 2.49 (br s, 
4H). 13C NMR (151 MHz, CDCl3) δ 162.0, 161.0, 157.0, 137.4, 129.2, 128.9, 122.7, 
95.2, 67.0, 57.3, 53.4, 37.7. HR-MS (ES) calcd for C16H21ClN5O [M+1]
+ 334.1435, 
found  334.1434. 
4.1.2.2. N2-(2-morpholinoethyl)-N4-(p-tolyl)pyrimidine-2,4-diamine (3b).  Yield: 0.013 
g, 21%. 1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 5.8 Hz, 1H), 7.22 (d, J = 8.1 Hz, 
2H), 7.15 (d, J = 8.1 Hz, 2H), 6.61 (br s, 1H), 5.99 (d, J = 5.8 Hz, 1H), 5.55 (br s, 1H), 
3.71 (t, J = 4.6 Hz, 4H), 3.48 (q, J = 5.8 Hz, 2H), 2.57 (t, J = 6.2 Hz, 2H), 2.48 (br s, 
4H), 2.33 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 162.1, 161.7, 156.7, 135.9, 134.2, 
129.8, 122.5, 94.6, 67.0, 57.4, 53.4, 37.7, 20.9. HR-MS (ES) calcd for C17H24N5O 
[M+1]+ 314.1981, found  314.1984. 
4.1.2.3. N4-((1,1'-biphenyl)-4-yl)-N2-(2-(morpholin-4-yl)ethyl)pyrimidine-2,4-diamine 
(3c). Yield: 0.020 g, 26%. 1H NMR (600 MHz, CDCl3) δ 7.97 (d, J = 5.8 Hz, 1H), 7.60 
– 7.56 (m, 4H), 7.47 – 7.42 (m, 4H), 7.36 – 7.31 (m, 1H), 6.58 (s, 1H), 6.08 (d, J = 5.8 
Hz, 1H), 5.46 (br s, 1H), 3.72 (t, J = 4.6 Hz, 4H), 3.52 (q, J = 5.8 Hz, 2H), 2.60 (t, J = 
6.2 Hz, 2H), 2.50 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 162.4, 161.3, 157.5, 140.6, 
138.3, 129.0, 128.0, 127.2, 126.9, 121.9, 67.1, 57.5, 53.6, 37.9. HR-MS (ES) calcd for 
C22H26N5O [M+1]
+ 376.2137, found 376.2140. 
4.1.2.4. N4-(4'-methyl-[1,1'-biphenyl]-4-yl)-N2-(2-morpholinoethyl)pyrimidine-2,4-
diamine (3d). Yield: 0.0145 g, 56 1H NMR (600 MHz, CDCl3) δ 7.94 (d, J = 5.8 Hz, 
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1H), 7.56 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 7.43 (d, J = 8.1 Hz, 2H), 7.25 (d, 
J = 7.6 Hz, 2H), 6.71 (s, 1H), 6.07 (d, J = 5.8 Hz, 1H), 5.61 (br s, 1H), 3.72 (t, J = 4.6 
Hz, 4H), 3.51 (q, J = 5.8 Hz, 2H), 2.60 (t, J = 6.1 Hz, 2H), 2.49 (t, J = 4.4 Hz, 4H), 2.39 
(s, 3H). 13C NMR (151 MHz, CDCl3) δ 162.2, 161.4, 157.0, 137.9, 137.7, 137.1, 137.0, 
129.7, 127.7, 126.8, 122.1, 95.2, 67.1, 57.5, 53.6, 7.9, 21.2. HR-MS (ES) calcd for 
C23H27N5O [M+H]
+ 390.2294, found 390.2302; [M+Na]+: 412.2113, found: 412.2113. 
4.1.2.5. N4-([1,1'-biphenyl]-4-yl)-N2-(2-(piperidin-1-yl)ethyl)pyrimidine-2,4-diamine 
(3e). Yield: 0.025 g, 36%. 1H NMR (600 MHz, CDCl3) δ 7.95 (d, J = 5.6 Hz, 1H), 7.60 
– 7.55 (m, 4H), 7.48 – 7.41 (m, 4H), 7.33 (t, J = 7.3 Hz, 1H), 6.82 (br s, 1H), 6.09 (d, J 
= 5.7 Hz, 1H), 5.64 (br s, 1H), 3.55 (q, J = 5.6 Hz, 2H), 2.63 (t, J = 6.1 Hz, 2H), 2.51 
(br s, 4H), 1.66 – 1.61 (m, 4H), 1.46 (br s, 2H). 13C NMR (151 MHz, CDCl3) δ 162.3, 
161.3, 157.2, 140.6, 138.4, 136.8, 128.9, 127.9, 127.2, 126.9, 121.9, 95.3, 57.7, 54.5, 
38.2, 25.7, 24.3. HR-MS (ES) calcd for C23H28N5 [M+1]
+ 374.2345, found 374.2322. 
4.1.2.6. N4-(4'-chloro-[1,1'-biphenyl]-4-yl)-N2-(2-(piperidin-1-yl)ethyl)pyrimidine-2,4-
diamine (3f). Yield: 0.014 g, 34%.1H NMR (600 MHz, CDCl3) δ 7.96 (d, J = 5.8 Hz, 
1H), 7.53 (d, J = 8.6 Hz, 2H), 7.50 (d, J = 8.5 Hz, 2H), 7.47 (d, J = 8.3 Hz, 2H), 7.40 (d, 
J = 8.5 Hz, 2H), 6.68 (s, 1H), 6.06 (d, J = 5.8 Hz, 1H), 5.65 (s, 1H), 3.52 (q, J = 5.8 Hz, 
2H), 2.60 (t, J = 6.2 Hz, 2H), 2.47 (s, 4H), 1.61 (p, J = 5.6 Hz, 4H), 1.45 (br s, 2H). 13C 
NMR (151 MHz, CDCl3) δ 162.3, 161.2, 157.3, 139.1, 138.7, 135.4, 133.3, 129.1, 
128.1, 127.8, 121.8, 57.7, 54.5, 38.3, 25.9, 24.4. HR-MS (ES) calcd for C23H26ClN5 
[M+H] + 408.1955, found: 408,1955. 
4.1.2.7. N4-(4-chlorophenyl)-N2-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-
diamine (3g). Yield: 0.0304 g, 41%. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 5.6 Hz, 
1H), 7.44 (d, J = 8.3 Hz, 2H), 7.27 (m, 1H), 7.25 (m, 1H), 6.51 (s, 1H), 5.93 (d, J = 5.7 
Hz, 1H), 4.81 (br s, 1H), 4.35 – 4.25 (m, 1H), 2.03 (dd, J = 12.7, 3.7 Hz, 2H), 1.31 (s, 
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6H), 1.16 (s, 6H), 0.98 (t, J = 12.2 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 161.8, 
161.0, 157.5, 137.9, 129.2, 128.6, 122.2, 95.7, 51.5, 45.8, 43.9, 35.0, 28.8. HR-MS (ES) 
calcd for C19H26ClN5 [M+H]
+ 360.1955, found 360.1951. 
4.1.2.8. N4-([1,1'-biphenyl]-4-yl)-N2-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-
diamine (3h). Yield: 0.026 g, 16%. 1H NMR (600 MHz, CDCl3) δ 7.94 (d, J = 5.6 Hz, 
1H), 7.57 – 7.55 (m, 6H), 7.44 (t, J = 7.9 Hz, 2H), 7.33 (t, J = 7.4 Hz, 1H), 6.70 (br s, 
1H), 6.02 (d, J = 5.6 Hz, 1H), 4.94 (br s, 1H), 4.40 – 4.31 (m, 1H), 2.06 (dd, J = 12.6, 
3.7 Hz, 2H), 1.34 (s, 6H), 1.18 (s, 6H), 1.05 (d, J = 12.0 Hz, 2H). 13C NMR (151 MHz, 
CDCl3) δ 161.8, 161.2, 157.2, 140.7, 138.5, 136.6, 129.0, 127.8, 127.2, 126.9, 121.5, 
95.7, 51.7, 45.6, 43.8, 34.9, 28.6. HR-MS (ES) calcd for C25H31N5 [M+H]
+ 402.2658, 
found 402.2658.  
4.1.2.9. N4-(4'-chloro-[1,1'-biphenyl]-4-yl)-N2-(2,2,6,6-tetramethylpiperidin-4-
yl)pyrimidine-2,4-diamine (3i). Yield: 0.0035 g, 6%. 1H NMR (600 MHz, CDCl3) δ 
7.90 (d, J = 5.4 Hz, 1H), 7.55 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 
8.4 Hz, 2H), 7.41 – 7.39 (m, 2H), 6.75 (br s, 1H), 6.01 (d, J = 5.7 Hz, 1H), 4.39-4.33 
(m, 1H), 2.05 (d, J = 3.7 Hz, 1H), 2.03 (s, 2H), 1.38 (s, 6H), 1.23 (s, 6H), 1.16 (t, J = 
12.2 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 161.3, 161.2, 139.0, 138.6, 135.4, 133.3, 
129.1, 128.1, 127.7, 121.5, 95.8, 52.5, 45.0, 43.6, 4.2, 29.8, 28.1. HR-MS (ES) calcd 
for C25H30ClN5 [M+H]
+: 436.2268, found 436.2266; [M+Na]+: 458.2087, found: 
458.2091 
4.1.2.10. N4-(3'-chloro-[1,1'-biphenyl]-4-yl)-N2-(2,2,6,6-tetramethylpiperidin-4-
yl)pyrimidine-2,4-diamine (3j). Yield: 0.0150 g, 11%. 1H NMR (600 MHz, CDCl3) δ 
7.93 (d, J = 5.4 Hz, 1H), 7.57 – 7.50 (m, 5H), 7.45 – 7.41 (m, 1H), 7.36 (t, J = 7.8 Hz, 
1H), 7.31 (dq, J = 8.0, 1.0 Hz, 1H), 6.66 (br s, 1H), 6.02 (d, J = 5.5 Hz, 1H), 5.21 (br s, 
1H), 4.38 – 4.33 (m, 1H), 2.08 – 2.03 (m, 2H), 1.39 (s, 6H), 1.25 (s, 6H), 1.18 – 1.14 
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(m, 2H). 13C NMR (151 MHz, CDCl3) δ 161.5, 161.1, 142.5, 139.0, 135.1, 134.9, 130.2, 
127.9, 127.2, 127.0, 125.0, 123.1, 121.4, 95.8, 45.0, 43.6, 34.2, 29.8, 28.1. HR-MS (ES) 
calcd for C25H31ClN5 [M+H]
+ 436.2268, found 436.2279.  
4.1.2.11. N4-(4'-methyl-[1,1'-biphenyl]-4-yl)-N2-(2,2,6,6-tetramethylpiperidin-4-
yl)pyrimidine-2,4-diamine (3k). Yield: 0.0062 g, 11%. 1H NMR (600 MHz, CDCl3) δ 
7.91 (d, J = 5.6 Hz, 1H), 7.54-7.52 (m, 4H), 7.46 (d, J = 7.8 Hz, 2H), 7.25 (d, J = 7.8 
Hz, 2H), 6.60 (br s, 1H), 6.01 (d, J = 5.7 Hz, 1H), 5.14 (br s, 1H), 4.38-4.32 (m, 1H), 
2.40 (s, 3H), 2.06 (d, J = 3.7 Hz, 1H), 2.04 (d, J = 3.5 Hz, 2H), 1.34 (s, 6H), 1.26 (s, 
6H), 1.05 (t, J = 12.0 Hz, 2H). 13C NMR. HR-MS (ES) calcd for C26H33N5 [M+H]
+ 
416.2814, found 416.2818. 
4.1.2.12. N4-(4-chlorophenyl)-N2-((pyridin-3-yl)methyl)pyrimidine-2,4-diamine (3l). 
Yield: 0.016 g, 26%. 1H NMR (600 MHz, CDCl3) δ 8.62 (s, 1H), 8.52 (d, J = 4.0 Hz, 
1H), 7.97 (d, J = 5.7 Hz, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.29 – 7.24 (m, 5H, signal 
overlapping with CDCl3), 6.44 (s, 1H), 6.01 (d, J = 5.8 Hz, 1H), 5.35 (br s, 1H), 4.64 (d, 
J = 6.0 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 162.2, 161.1, 157.6, 149.2, 148.8, 
137.4, 135.2, 135.1, 129.3, 125.8, 123.6, 122.9, 43.1. HR-MS (ES) calcd for C16H15ClN5 
[M+1]+ 312.1016, found 312.1018. 
4.1.2.13. N4-([1,1'-biphenyl]-4-yl)-N2-(pyridin-3-ylmethyl)pyrimidine-2,4-diamine 
(3m). Yield: 0.024 g, 27%.  1H NMR (500 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.57 (s, 1H), 
8.42 (dd, J = 4.70, 1.5 Hz, 1H), 7.88 (d, J = 5.7 Hz, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.63 – 
7.61 (m, 3H), 7.53 (d, , J = 6.5 Hz , 2H), 7.45 – 7.42 (m, 3H), 7.34 – 7.29 (m, 2H), 6.05 
(d, J = 5.6 Hz, 1H), 4.51 (d, J = 6.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 158.3, 
154.3, 151.6, 140.9, 140.5, 135.1, 133.4, 128.9, 128.8, 128.7, 127.6, 127.4, 127.2, 






diamine (3n). Yield: 0.010 g, 21%. 1H NMR (500 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.58 
(s, 1H), 8.43 (dd, J = 4.7, 1.6 Hz, 1H), 7.89 (d, J = 5.7 Hz, 1H), 7.77 – 7.73 (m, 1H), 
7.68 – 7.65 (m, 2H), 7.58 – 7.44 (m, 5 H), 7.36 – 7.33 (m, 1H), 6.06 (d, J = 5.6 Hz, 1H), 
4.52 (d, J = 6.2 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 161.7, 160.4, 160.4, 156.2, 
148.6, 147.6, 140.2, 138.7, 138.6, 136.1, 134.6, 131.6, 131.4, 128.7, 127.7, 126.6, 
123.3, 123.2, 119.5, 41.9. HR-MS (ES) calcd for C22H18ClN5 [M+H]
+ 388.1329, found 
388.1325   
4.1.2.15. N4-(3'-chloro-[1,1'-biphenyl]-4-yl)-N2-(pyridin-3-ylmethyl)pyrimidine-2,4-
diamine (3o). Yield: 0.013 g, 21%. 1H NMR (600 MHz, CDCl3) δ 8.64 (br s, 1H), 8.52 
(d, J = 4.6 Hz, 1H), 7.99 (d, J = 5.8 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.57 – 7.54 (m, 
1H), 7.52 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 8.5 Hz, 2H), 7.36 (t, 
J = 7.9 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.28 – 7.24 (m, 1H, signal overlapping with 
CDCl3), 6.58 (s, 1H), 6.11 (d, J = 5.7 Hz, 1H), 5.40 (br s, 1H), 4.66 (d, J = 6.1 Hz, 2H). 
13C NMR (151 MHz, CDCl3) δ 171.8, 161.1, 157.3, 149.1, 148.6, 142.3, 138.5, 13 .3, 
135.1, 135.0, 134.7, 130.0, 127.8, 127.1, 126.9, 124.9, 123.4, 122.0, 121.7, 43.0. HR-
MS (ES) calcd for C22H19ClN5 [M+1]
+ 388.1329, found 388.1329. 
4.1.2.16. 3-(((4-([1,1'-biphenyl]-4-ylamino)pyrimidin-2-yl)amino)methyl)pyridine 1-
oxide (3p). Yield: 0.0071 g, 26%. 1H NMR (600 MHz, CDCl3) δ 8.31 (s, 1H), 8.11 (d, J 
= 6.3 Hz, 1H), 7.93 (d, J = 5.8 Hz, 1H), 7.59 – 7.53 (m, 4H), 7.44 (t, J = 7.6 Hz, 2H), 
7.39 (d, J = 8.2 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.22 (t, J = 
6.4 Hz, 1H), 6.84 (s, 1H), 6.14 (d, J = 5.8 Hz, 1H), 5.65 (br s, 1H), 4.60 (d, J = 6.2 Hz, 
2H). 13C NMR (151 MHz, CDCl3) δ 162.0, 161.9, 161.4, 157.2, 140.5, 140.0, 138.5, 
137.9, 137.8, 137.2, 129.0, 127.9, 127.3, 127.0, 125.8, 125.2, 122.2, 42.4. HR-MS (ES) 
calcd for C22H20N5O [M+1]
+ 370.1668, found 370.1679.  
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4.1.2.17. N-([1,1'-biphenyl]-4-yl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (3q). 
Yield: 0.019 g, 22%. 1H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 5.7 Hz, 1H), 7.60 – 
7.56 (m, 4H), 7.46 – 7.41 (m, 4H), 7.33 (t, J = 7.4 Hz, 1H), 6.59 (br s, 1H), 6.05 (d, J = 
5.7 Hz, 1H), 3.85 (t, J = 5.1 Hz, 4H), 2.50 (t, J = 5.1 Hz, 4H), 2.35 (s, 3H). 13C NMR 
(151 MHz, CDCl3) δ 161.9, 161.0, 157.3, 140.6, 138.4, 136.7, 128.9, 127.9, 127.2, 
126.9, 121.7, 95.0, 55.1, 46.3, 43.8. HR-MS (ES) calcd for C21H24N5 [M+1]
+ 346.2032, 
found 346.2151.  
4.1.2.18. N-(4'-chloro-[1,1'-biphenyl]-4-yl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-
amine (3r). Yield: 0.0039 g, 23%. 1H NMR (600 MHz, CDCl3) δ 8.02 (d, J = 5.7 Hz, 
1H), 7.55 – 7.52 (m, 2H), 7.52 – 7.50 (m, 2H), 7.47 – .44 (m, 2H), 7.41 – 7.39 (m, 
2H), 6.54 (br s, 1H), 6.03 (d, J = 5.7 Hz, 1H), 3.86 – 3.81 (m, 3H), 2.49 (t, J = 5.1 Hz, 
4H), 2.35 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 161.9, 160.8, 157.4, 139.1, 138.8, 
135.3, 133.3, 129.1, 128.1, 127.7, 121.6, 95.1, 55.1, 46.4, 43.9, 29.8. HR-MS (ES) calcd 
for C21H22ClN5 [M+H]+ 380.1642, found 380.1634.  
4.1.2.19. N-(3'-chloro-[1,1'-biphenyl]-4-yl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-
amine. (3s). Yield: 0.0296 g, 49%. 1H NMR (600 MHz, CDCl3) δ 8.03 (d, J = 5.7 Hz, 
1H), 7.58 – 7.52 (m, 3H), 7.49 – 7.44 (m, 3H), 7.36 (t, J = 7.8 Hz, 1H), 7.30 (dq, J = 
7.9, 1.0 Hz, 1H), 6.61 (br s, 1H), 6.03 (d, J = 5.7 Hz, 1H), 3.84 (t, J = 4.5 Hz, 4H), 2.48 
(t, J = 5.0 Hz, 4H), 2.34 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 161.9, 160.8, 157.3, 
142.5, 139.0, 135.0, 134.8, 130.2, 128.9, 127.9, 127.2, 127.0, 126.9, 125.0, 121.5, 95.1, 
55.1, 46.4, 43.9. HR-MS (ES) calcd for C21H23ClN5 [M+H]
+ 380.1642, found 380.1629. 
4.1.2.20. N-(4'-methyl-[1,1'-biphenyl]-4-yl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-
amine (3t). Yield: 0.0117 g, 49%. 1H NMR (600 MHz, CDCl3) δ 8.01 (d, J = 5.7 Hz, 
1H), 7.57 - 7.55 (m, 2H), 7.49 - 7.47 (m, 2H), 7.43 - 7.41 (m, 2H), 7.26 – 7.24 (m, 2H), 
6.50 (br s, 1H), 6.04 (d, J = 5.7 Hz, 1H), 3.84 (t, J = 5.2 Hz, 4H), 2.50 (t, J = 5.2 Hz, 
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4H), 2.40 (s, 3H), 2.35 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 161.9, 161.0, 157.3, 
138.1, 137.7, 137.0, 136.7, 129.7, 127.7, 126.8, 121.8, 94.9, 55.2, 46.4, 43.8, 29.8. HR-
MS (ES) calcd for C22H25N5 [M+H]
+ 360.2188, found 360.2188; [M+Na]+ 382.2008, 
found: 382.1991 
4.1.2.21. 2-(4-(4-((4-chlorophenyl)amino)pyrimidin-2-yl)piperazin-1-yl)ethan-1-ol (3u). 
Yield: 0.020 g, 30%. 1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 5.7 Hz, 1H), 7.34 – 
7.26 (m, 4H), 6.49 (br s, 1H), 5.95 (d, J = 5.7 Hz, 1H), 3.80 (t, J = 5.0 Hz , 4H), 3.66 (t, 
J = 5.3 Hz, 2H), 2.60 – 2.55 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 161.8, 160.8, 
157.4, 137.7, 129.3, 128.8, 122.7, 95.0, 59.6, 57.9, 53.0, 44.0. HR-MS (ES) calcd for 
C16H21ClN5O [M+1]
+ 334.1435, found 334.1488. 
4.1.2.22. 2-(4-(4-(((1,1'-biphenyl)-4-yl)amino)pyrimidin-2-yl)piperazin-1-yl)ethan-1-ol 
(3v). Yield: 0.017 g, 25%. 1H NMR (600 MHz, CDCl3) δ 8.02 (d, J = 5.7 Hz, 1H), 7.60 
– 7.56 (m, 4H), 7.47 – 7.41 (m, 4H), 7.33 (t, J = 7.4 Hz, 1H), 6.72 (s, 1H), 6.05 (d, J = 
5.7 Hz, 1H), 3.84 (t, J = 4.9 Hz, 4H), 3.68 (t, J = 5.2 Hz, 2H), 2.61 – 2.56 (m, 7H). 13C 
NMR (151 MHz, CDCl3) δ 161.9, 161.0, 157.3, 140.6, 138.3, 136.8, 129.0, 127.9, 
127.2, 126.9, 121.8, 95.0, 59.6, 57.9, 53.0, 43.9. HR-MS (ES) calcd for C22H26N5O 
[M+1]+ 376.2137, found  376.2143.  
4.1.3. General procedure for the synthesis of compounds 4a-d. DIPEA was added (3.6 
mmol) to a round-bottom flask containing a mixture of 2,4-dichloropirimidine (1) (3.3 
mmol) and the corresponding amine (3.3 mmol) in ethanol (10 mL) at 0ºC. The reaction 
mixture was stirred for 5 minutes at 0oC and then refluxed at 90oC overnight. The 
solvent was evaporated in vacuo. The residue was re-dissolved in a mixture of ethyl 
acetate and dichloromethane and washed with a NaHCO3 solution and brine. The 
aqueous layer was washed with ethyl acetate. The combined organic layer was dried 
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over anhydrous Na2SO4 and concentrated in vacuo. The products were obtained as 
solids, which were recrystallized from ethanol. 
4.1.3.1. 2-chloro-N-(4-chlorobenzyl)pyrimidin-4-amine (4a). Yield: 0.7436 g, 87%. 1H 
NMR (600 MHz, CDCl3) δ 8.03 (d, J = 5.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.25 (d, J
= 8.3 Hz, 2H), 6.23 (d, J = 5.6 Hz, 1H), 5.72 (br s, 1H), 4.53 (br s, 2H). 
4.1.3.2. 2-chloro-N-(4-fluorobenzyl)pyrimidin-4-amine (4b). Yield: 0.5438 g, 68%. 1H 
NMR (600 MHz, CDCl3) δ 8.03 (d, J = 4.6 Hz, 1H), 7.31 – 7.27 (m, 2H), 7.05 (d, J = 
8.5 Hz, 2H), 6.23 (d, J = 5.7 Hz, 1H), 5.37 (br s, 1H), 4.53 (br s, 2H). 
4.1.3.3. 2-chloro-N-(4-methylbenzyl)pyrimidin-4-amine (4c). Yield: 0.5744 g, 73%. 1H 
NMR (600 MHz, CDCl3) δ 8.00 (s, 1H), 7.20 (d, J = 7.8 Hz, 2H), 7.17 (d, J = 7.9 Hz, 
2H), 6.23 (d, J = 6.0 Hz, 1H), 5.27 (br s, 1H), 4.49 (br s, 2H), 2.34 (s, 3H). 
4.1.3.4. 2-chloro-N-(4-methoxybenzyl)pyrimidin-4-amine (4d). Yield: 0.3732 g, 56%. 
1H NMR (600 MHz, CDCl3) δ 8.01 (s, 1H), 7.23 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.6 
Hz, 2H), 6.23 (d, J = 6.1 Hz, 1H), 5.22 (br s, 1H), 4.46 (br s, 2H), 3.80 (s, 3H). 
4.1.4. General procedure for the synthesis of compounds 5a-e. Compounds 5a-e were 
synthesized as described before for compounds 3a-v.  
4.1.4.1 N4-(4-chlorobenzyl)-N2-(pyridin-3-ylmethyl)pyrimidine-2,4-diamine (5a). Yield: 
0.150 g, 39%. 1H NMR (600 MHz, CDCl3) δ 8.58 (s, 1H), 8.49 (d, J = 3.7 Hz, 1 H), 
7.84 (d, J = 5.3 Hz, 1H), 7.62 (d, J = 7.0 Hz, 1H), 7.28 – 7.26 (m, 2H, signal 
overlapping with CDCl3), 7.23 – 7.18 (m, 3H), 5.74 (d, J = 5.7 Hz, 1H), 5.32 (br s, 1H), 
4.98 (br s, 1H), 4.58 (d, J = 5.9 Hz, 2H), 4.47 (d, J = 4.5 Hz, 2H).  13C NMR (151 MHz, 
CDCl3) δ 163.0, 162.1, 156.4, 149.2, 148.5, 137.3, 135.5, 13 .2, 133.2, 128.9, 128.8, 
123.5, 44.4, 42.9. HR-MS (ES) calcd for C17H17ClN5 [M+H]





diamine (5b). Yield: 0.0228 g, 17%. 1H NMR (600 MHz, CDCl3) δ 7.81 (d, J = 5.3 Hz, 
1H), 7.30 (d, J = 8.1 Hz, 2H), 7.24 (d, J = 8.1 Hz,2H), 5.71 (d, J = 5.6 Hz, 1H), 4.97 (br 
s, 1H), 4.83 (br s, 1H), 4.53 (br, s,2 H), 4.26 – 4.23 (m, 1H), 1.99 (dd, J = 12.5, 3.2 Hz, 
2H), 1.26 (s, 6H), 1.20 (s, 6H), 1.08 (t, J = 10.2 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 
163.0, 161.8, 156.6, 137.6, 133.3, 128.9, 128.8, 94.7, 51.9, 45.7, 43.8, 34.9, 28.5. HR-
MS (ES) calcd for C20H29ClN5 [M+H]
+ 374.2111, found 374.2144. 
4.1.4.3. N4-(4-fluorobenzyl)-N2-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-
diamine (5c). Yield: 0.0243 g, 16%. 1H NMR (600 MHz, CDCl3) δ 7.81 (d, J = 5.6 Hz, 
1H), 7.31 – 7.26 (m, 2H, signal overlapping with CDl3), 7.04 – 6.96 (m, 2H), 5.70 (d, 
J = 5.7 Hz, 1H), 4.94 (br s, 1H), 4.82 (br s, 1H), 4.57 – 4.51 (m, 2 H), 4.29 – 4.22 (m, 
1H), 2.02 – 1.97 (m, 2H), 1.24 (s, 6H), 1.16 (s, 6H), 1.01 – 0.97 (m, 2H). 13C NMR (151 
MHz, CDCl3) δ 162.9, 161.5, 129.0, 128.9, 115.6, 115.4, 115.3, 115.2, 51.8, 45.3, 44.5, 
43.6, 34.6, 28.2. HR-MS (ES) calcd for C20H29FN5 [M+H]
+ 358.2407, found 358.2420. 
4.1.4.4. N4-(4-methylbenzyl)-N2-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-
diamine (5d). Yield: 0.0243 g, 16 %. 1H NMR (600 MHz, CDCl3) δ 7.76 (s, 1H), 7.23 - 
7.18 (m, 2H), 7.16 – 7.10 (m, 2H), 5.70 (d, J = 5.9 Hz, 1H), 5.35 (br s, 1H), 5.01 (br s, 
1H), 4.55 – 4.50 (m, 2 H), 4.30 – 4.24 (m, 1H), 2.33 (d, J = 9.0 Hz, 3H), 1.99 (dd, J = 
12.5, 3.6 Hz, 2H), 1.24 (d, J = 4.7 Hz, 6H), 1.18 (d, J = 5.4 Hz, 6H), 1.07 – 1.02 (m, 
2H). 13C NMR (151 MHz, CDCl3) δ 144.7, 137.3, 136.7, 129.5, 129.3, 127.6, 125.1, 
54.4, 52.2, 45.1, 43.6, 34.4, 28.1, 21.2. HR-MS (ES) calcd for C21H32N5 [M+H]
+ 
354.2658, found 354.2673. 
4.1.4.5. N4-(4-methoxybenzyl)-N2-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-
diamine (5e). Yield: 0.055 g, 35%. 1H NMR (600 MHz, CDCl3) δ 7.78 (br s, 1H), 7.24 
(d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.71 (d, J = 5.9 Hz, 1H), 4.92 (br s, 1H), 
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4.48 (br s, 2H), 4.33 – 4.27 (m, 1H), 3.80 (s, 3H), 2.02 (dd, J = 12.6, 3.4 Hz, 2H), 1.29 
(br s, 6H), 1.21 (br s, 6H), 0.90 – 0.83 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 164.2, 
163.0, 161.8, 159.2, 156.5, 155.4, 128.9, 114.2, 55.5, 51.5, 45.8, 43.8, 35.1, 29.9, 28.6. 
HR-MS (ES) calcd for C21H32N5O [M+H]
+ 370.2607, found 370.2633. 
4.1.5. 2-chloro-4-hydrazinylpyrimidine (6). A mixture of 2,4-dichloropyrimidine (1) (70 
mmol) and TEA (70 mmol) in methanol (5 mL) was cooled to 0-5 ºC in an ice bath. 
Hydrazine hydrate (80 mmol) was added slowly dropwise to the cold reaction. Then, the 
reaction mixture was allowed to stir at room temperature for 2 h. The solid obtained was 
filtered, washed with chilled water and dried under vacuum overnight to afford 6. Yield: 
0.4 g, 40%. 
4.1.6. (E)-2-chloro-4-(2-(2,4-dichlorobenzylidene)hydrazinyl)pyrimidine (7). 
Compound 6 (0.76 mmol) was dissolved in EtOH (3 mL) and 2,4-dichlorobenzaldehyde 
(0.91 mol) was added to the mixture. The mixture was refluxed for 1 h and allowed to 
stand at room temperature. The solid was filtered, washed with EtOH and dried to 
afford compound 7. Yield: 0.3 g, 100%. 1H NMR (500 MHz, DMSO-d6) δ 12.15 (s, 
1H), 8.46 (s, 1H), 8.31 (d, J = 5.8 Hz, 1H), 8.10 (d, J = 8.6 Hz, 1H), 7.73 (d, J = 2.1 Hz, 
1H), 7.51 (dd, J = 8.6, 2.0 Hz, 1H), 7.27 (s, 1H). 
4.1.7. (E)-4-(2-(2,4-dichlorobenzylidene)hydrazinyl)-N-(2-morpholinoethyl)pyrimidin-
2-amine (8). Compound 8 was synthesized as described before for compounds 3a-v.
Yield: 0.09 g, 3%. 1H NMR (500 MHz, CDCl3) δ 8.41 (br s, 1H), 8.11 – 8.06 (m, 2H), 
7.98 (d, J = 8.6 Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.28 (dd, J = 8.6, 2.0 Hz, 1H), 6.59 
(d, J = 5.7 Hz, 1H), 5.57 (br s, 1H), 3.72 (t, J = 4.6 Hz, 4H), 3.49 – 3.44 (m, 3H), 2.59 
(t, J = 6.1 Hz, 2H), 2.49 (s, 4H). 13C NMR (151 MHz, CDCl3) δ 161.9, 161.8, 157.8, 
135.7, 133.9, 133.2, 130.5, 129.8, 127.9, 127.7, 67.1, 57.4, 53.6, 37.8. HR-MS (ES) 
calcd for C17H21Cl2N6O [M+H]
+ 395.1154, found 395.1126. 
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4.1.8. 2-chloropyrimidine-4-amine (9). A suspension of 2,4-dichloropyrimidine (1) (4.0 
mmol) in ammonium hydroxide (4.0 mmol) was stirred at 90ºC for 5 h. The mixture 
was cooled to room temperature and a white solid preci itated. The solid was filtered 
out and washed with ethyl ether. Yield: 0.23 g, 45 %. 1H NMR (600 MHz, CDCl3) δ 
8.16 (d, J = 5.2 Hz, 1H), 6.66 (d, J = 5.2 Hz, 1H), 5.21 (br s, 2H). 
4.1.9. N-(2-chloropyrimidin-4-yl)-5-(pyridin-2-yl)thiophene-2-carboxamide (10). In a 
botton flask purged with nitrogen, 5-(pyridin-2-yl)thiophene-2-carboxylic acid (0.24 
mmol) was added in portions to a mixture of 9 (0.27 mmol), EDCI·HCl (0.27 mmol) 
and HOBt (0.12 mmol) in N-methylpyrrolidin-2-one (2 mL). The mixture was stirred at 
room temperature overnight. Water (10 mL) and ethyl acetate (10 mL) were added, and 
the mixture was stirred for 10 min. The mixture was p rtitioned, and the aqueous phase 
was extracted twice with ethyl acetate. The combined organic extracts were 
concentrated under vacuo. The product (10) was obtained after purification by 
preparative chromatography (SiO2, dichlorometane:methanol). The yellow solid product 
was used in the next step without further purification. Yield: 0.0088 g, 11%. 
4.1.10. N-(2-((2-morpholinoethyl)amino)pyrimidin-4-yl)-5-(pyridin-2-yl)thiophene-2-
carboxamide (11). Compound 11 was synthesized as described before for compounds 
3a-v. Yield: 0.004 g, 36%. 1H NMR (500 MHz, CDCl3) δ 9.5, (s, 1H), 8.60 (d, J = 4.8 
Hz, 1H), 7.75 – 7.64 (m, 3H), 7.57 (d, J = 3.9 Hz, 1H), 7.54 (d, J = 3.9 Hz, 2H), 7.22 
(dd, J = 7.2, 6.3 Hz, 1H), 6.64 (br s, 1H), 3.75 (t, J = 4.6 Hz, 4H), 3.55 (q, J = 5.5 Hz, 
2H), 2.60 (t, J = 5.9 Hz, 2H), 2.51 (t, J = 4.7 Hz, 4H). 13C NMR (151 MHz, CDCl3) δ 
162.0, 161.4, 151.9, 149.9, 148.6, 139.4, 137.0, 13.0, 124.8, 123.0, 119.3, 67.1, 57.1, 
53.6, 29.9. HR-MS (ES) calcd for C20H22N6O2S [M+H]
+ 411.1603,  
4.1.11. N-([1,1'-biphenyl]-4-yl)-2-(2-morpholinoethoxy)pyrimidin-4-amine (12). A 
mixture of a NaH (0.46 mmol) and 4-(2-hydroxyethyl)morpholine (0.46 mmol) in THF 
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(1.5 mL) was stirred at 0ºC. The reaction was allowed to warm at room temperature and 
stirred for 30 minutes. After this period, compound 2c was added under nitrogen 
atmosphere, the vial was sealed and the mixture was stirred and heated at 80 oC 
overnight. The reaction solution was poured into water and extracted with 
dichloromethane. The organic layer was sequentially washed with brine, dried over 
anhydrous Na2SO4 and concentrated in vacuo. The crude product was purified by 
column chromatography (SiO2, dichloromethane/methanol). Yield: 0.0171 g, 25%. 
1H 
NMR (600 MHz, CDCl3) δ 8.10 (d, J = 5.8 Hz, 1H), 7.61 – 7.56 (m, 4H), 7.47 – 7.41 
(m, 4H), 7.35 (t, J = 7.4 Hz, 1H), 7.15 (br s, 1H), 6.40 (d, J = 5.8 Hz, 1H), 4.47 (t, J = 
5.7 Hz, 2H), 3.71 (t, J = 4.5 Hz, 4H), 2.79 (t, J = 5.9 Hz, 2H), 2.57 (br s, 4H). 13C NMR 
(151 MHz, CDCl3) δ 165.2, 162.7, 158.1, 140.4, 137.8, 137.5, 129.0, 128.1, 127.4, 
127.0, 122.7, 99.0, 67.1, 64.8, 57.5, 54.1. HR-MS (E ) calcd for C22H25N4O2 [M+H]
+ 
377.1978, found 377.1925. 
4.2. Biological studies 
4.2.1. Antiviral assay using DENV reporter 
One day prior to infection, A549 or BHK-21 cells were seeded in a 24-well plate. The 
next day, cells were infected with luciferase reporter infectious DENV at MOI of 1 [36] 
in the absence or presence of compounds to be tested. Controls included uninfected 
cells, infected cells, and DMSO-treated infected cells. Prior to infection, the viral 
inoculum was incubated 30 min in the presence of each compound. The viral inoculum 
was removed from the cells 1 h later, and incubated with fresh medium containing the 
compound. Luciferase activity was measured at 8 h and 24 h postinfection p.i. using the 
Renilla luciferase assay system according to the manufacturer’s protocol (Promega). 
These time points allow discrimination between early steps of viral infection (entry- 
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translation of incoming genome) up to 8 h and, genome RNA amplification, evident 
after 24 h of infection [19].  
4.2.2. Cytotoxicity test 
Cell viability was measured by two different assays: MTT and crystal violet (CV). Vero 
cell confluent cultures (African green monkey kidney, ATCC CCL-81) grown in Eagle's 
minimum essential medium (MEM) (Gibco™ Thermo Fisher Scientific, Carlsbad, CA) 
supplemented with 5% inactivated bovine serum were exposed for 48 h to serial twofold 
compound dilutions, three wells for each concentration, and then viability was tested. In 
the MTT method, 10 mL of MM containing MTT (final concentration 0.5 mg/mL ) was 
added to each well. After 2 h of incubation, the supernatant was removed, ethanol was 
added to each well and absorbance was measured at 595 nm. For CV assay, cells were 
fixed with 10 % formaldehyde during 15 min. Then, cells were washed with water and 
stained with CV (0.05 % CV in 10 % ethanol) during 30 min. After washing, colourant 
was eluted with ethanol/acetic acid, 50/0.1% and absorbance was recorded at 590 nm 
[21]. The cytotoxic concentration 50% (CC50) was calculated as the compound 
concentration required to reduce the absorbance signal by 50% compared to untreated 
controls.   
4.2.3. Viral infection in cells and quantification f viral titers. Virus stocks of DENV-1 
(Hawaii), DENV-2 (New Guinea C), DENV-3 (H87) and DENV-4 (8124) were 
provided by Dr. A.S. Mistchenko (Hospital de Niños Dr. Ricardo Gutierrez, Buenos 
Aires, Argentina). All the stocks were prepared in C6/36 cells and titrated by a standard 
plaque assay in Vero cells. For plaque assay, 10-fold dilutions of samples containing 
virus were added to monolayers of confluent Vero cells at 37°C for 1 h. Following 
incubation, the inoculum was removed, and monolayers were overlaid with 1 mL of 
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MEM containing 1% methylcellulose. The cells were incubated at 37°C for 7 days and 
fixed using 4% formaldehyde. Finally, plaques were stained with 0.1% crystal violet in 
20% ethanol. 
4.2.4 Virus yield reduction assay Vero cells grown in 24 well plates were infected at 
m.o.i. 0.1 PFU/cell. After 1 h adsorption at 4°C, cells were washed and refed with
maintenance medium containing or not serial two fold dilutions of each tested 
compound respectively. After 24 and 48 h of incubation at 37°C, supernatant cultures 
were harvested and extracellular virus yields were determined by a plaque assay. The 
effective concentration 50% (EC50) was calculated as the concentration required to 
reduce virus yield by 50% in the compound treated cultures compared with untreated 
ones. All determinations were performed in triplicate. 
4.2.5.Virus RNA synthesis. Cells were infected at a m.o.i. of 1. At 24 h p.i., 
extracellular medium was harvested to quantify virus production and cells were 
processed for real time RT-PCR assays. Total RNA was extracted by using TRIZOL 
(Invitrogen Life Technologies) according to the manufacturer’s instructions. Then, 
cDNA was generated by using murine reverse transcriptase M-MLV (100 U/µL, 
Invitrogen) and random primers. This cDNA was amplified by real time PCR using 
SYBRGreen (Roche) detection. The mix reaction volume was 25 µl including 2 µL of 
cDNA, DNA polymerase GoTaq (5 U/µL, Promega) and specific primers to amplify all 
DENV serotypes: Sense 5′ -TTGAGTAAACYRTGCTGCCTGTAGCTC-3′
Antisense 5’ -GGGTCTCCTCTAACCTCTAGTCCT-3′ . Real time PCR was 
carried out with an initial incubation at 95°C during 2 min, followed by 35 cycles of 30 
s at 95°C, 1 min at 58°C, and 1 min at 72°C and a fin l step of 10 min at 72°C. 
Amplification plots were analyzed with Opticon Monitor 3.1 software and the 
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comparative threshold cycle (Ct) method was used to determine gene expression 
relative to the cellular gene β-actin. Statistical analyses were performed using GraphPad 
Prism software. Comparison of means was tested by one‐way analysis of variance 
(ANOVA) with Dunnett's posttest. Statistical significance was defined as P < 0.05 (95% 
confidence interval). 
4.3. Molecular docking 
Docking studies were performed on the β-OG binding site of the Dengue E protein 
(PDB ID 1OKE).  The system was described in terms of dihedral coordinates using the 
ECEPP/3 force field [37] as implemented in the Inter al Coordinates Mechanics (ICM) 
program (version 3.7-2c, MolSoft LLC, La Jolla, CA) [38], and prepared in a similar 
fashion as earlier works [23,39]: water molecules were deleted; hydrogen atoms were 
added to the receptor structure;  Asp and Glu amino-acids were assigned a −1 negative 
charge, and Arg and Lys amino-acids a +1 charge. Histidine tautomers were selected 
based on the hydrogen bonding network. The rigid-receptor:flexible-ligand docking 
protocol as implemented in ICM was used. The receptor was represented by six 
potential energy maps. The six rigid degrees of freedom and torsion angles were 
considered flexible during the docking procedure, and subjected to a global energy 
minimization protocol within the field of the receptor using a Monte Carlo with 
minimization protocol [38,40].  
 
 
4.4. Molecular dynamics 
MD simulations were performed using Amber16 and AmberTools16 package [41] using 
the Amber99SB force field [42]. The system was solvated with the TIP3P water model 
in a truncated octahedric box, extending 10 Å from the protein, and neutralized adding 
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sufficient Na+ ions. Bond lengths were constrained using the SHAKE algorithm 
allowing a 2 fs time-step. Long-range electrostatics interactions were taken into account 
using the particle-mesh Ewald (PME) approach. The non bonded cut-off for Coulomb 
and Van der Waals interactions were both 8 Å. Energy minimization was conducted 
through the steepest-descent algorithm and then switched to conjugate gradient. Then an 
equilibration of the whole system was performed during 100 ps of NVT simulation 
followed by 400 ps of NPT simulation. Temperature was kept constant at 300 K using a 
Langevin thermostat [43] with a collision frequency of 2 ps. Constant pressure of 1 bar 
was applied in all directions with a pressure relaxation time of 1.0 ps. 
Binding free energy was estimated with the Molecular Mechanics/Generalized Born 
Surface Area (MM/GBSA) method, using the MMPBSA.py [44] module implemented 
in Amber analysis tools. 
4.5. Shake-flask method for drug solubility testing  
The shake-flask method was used as a reference assay [45–47]. Test compounds (1.0 
mg) were weighed into 2 mL glass vial, and 1 mL of the medium (simulated gastric 
fluid (SGF), simulated intestinal fluid (SIF) and phosphate buffered saline solution 
(PBS)) was added. The vial contents were mixed at 1500 rpm at 37 oC for 24 h and then 
incubated at 37 ºC for 24 h. The sample was filtered (0.2 µm, Sterile Acrodisc® 13, 
GelmanScience) before analysis with UV3600 UV-VIS-NIR Spectrophotometer. 
Calibration curves were obtained from compounds over a wide concentration range and 
were constructed by plotting absorbance of the compounds against the concentration. 
All compounds were test in triplicate. 
4.6. SGF, SIF and PBS stability 
Stock solutions of test compounds were prepared at a concentration of 10 mM in 
DMSO. The stock solution was diluted in acetonitrile to 1 mM. The reactions were 
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initiated by the addition of the test compounds to the medium (SGF, SIF and PBS) 
(final concentration: 50 µM). Samples were incubated in a shaking water bath at 37ºC 
and conducted in triplicate. Samples (125 µL) were taken at 0, 15, 30, 60, 90, 120 min 
and 375 µL of acetonitrile containing the internal standard (warfarin) was added to 
quench the reaction. The samples were vortexed for 1 min and then centrifugated at 
25ºC for 15 min at 14000 rpm. The supernatant was collected, diluted in methanol:water 
(50:50) and analyzed by high performance liquid chromatography-mass spectrometry 
(HPLC-MS). The quantification was based on the peak area ratio of the test compound 
vs. the internal standard. 
The HPLC-MS analysis was performed using a Waters Alliance e2695 system fitted 
with a Waters XBridge C18 (4.6 x 150 mm, 3.5 µm particle size, Waters Corporation, 
Milford, MA, USA), coupled to a Waters SQD2 single quadrupole mass spectrometer 
with an electrospray ionization (ESI) source. Gradient elution was utilized in the 
chromatographic separation method using 60% acetonitrile, 40% water, 0.1% acetic 
acid and 10 mM ammonium acetate (mobile phase A), 90% isopropanol, 10 % 
acetonitrile, 0.1% acetic acid and 10 mM ammonium acetate (mobile phase B), with the 
following program: 0-5 min 5% B; 5-13 min 5-95% B; 13-15 min 95%. The flow rate 
was constant at 0.3 mL min-1. After each sample injection, the gradient was returned to 
its initial conditions in 12 min. The injection volume was 5 µL. The column temperature 
was 35ºC. The mass spectrometer was operated in postive ion mode with a probe 
capillary voltage of 3.0 kV. The sampling cone voltage was set to 45.0 V. The source 
and desolvation gas temperatures were set at 150°C and 350°C, respectively. The 
nitrogen gas desolvation flow rate was 600 L h–1 and the cone gas flow rate was 10 L h–
1. The mass spectrometer was calibrated across the rang  of m/z 20–2023 with a sodium 
and cesium iodide solution. Data were acquired in scan mode with a scan duration of 
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0.2 sec, and in SIRmode with unit resolution. Data cquisition and processing were 
carried out using MassLynx, version 4.1 software.  
4.7. Mouse plasma stability 
Stock solutions of test compounds were prepared at a concentration of 10 mM in 
DMSO. The stock solution was diluted in DMSO to 1 mM. The mouse plasma was 
diluted to 80% with PBS. The reactions were initiated by the addition of the test 
compounds to the preheated plasma solution (final concentration: 50 µM). Samples 
were incubated in a shaking water bath at 37 ºC and co ucted in triplicate. Samples (50 
µL) were taken at 0, 15, 30, 60, 90, 120 min and 200 µL of cold acetonitrile containing 
the internal standard (warfarin) was added to deprot inize the plasma. The samples were 
vortexed for 1 min and then centrifugated at 4 ºC for 15 min at 14000 rpm. Enalapril 
was used as positive control incubation. The supernatant was collected, diluted in 
methanol: water (50:50) and analyzed by HPLC-MS. The quantification was based on 
the peak area ratio of the test compound vs. the internal standard. The HPLC-MS 
analysis was performed as described before for SGF, IF and PBS stability.  
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• De novo design approach was used to identify new compounds against DENV E protein 
• Lead Optimization was performed via molecular dynamics 
• Several compounds displayed excellent potency against DENV 
• Compounds 3e and 3h were potent compounds of all four sero-types of DENV  
• 3e and 3h showed acceptable in vitro pharmacokinetics profile. 
 
